LLY Q2 2026 Earnings Analysis

Big is an understatement. But before we get into the numbers, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

That's a company firing on basically every cylinder. And the incretin franchise — Zepbound and Mounjaro — is still the engine room. Combined, those two brought in $14.9 billion in the quarter, contributing $6.3 billion of the total growth.

Which, by the way, is up $3 billion at the low end and $2 billion at the high end from prior guidance. That's not a small tweak — that's a company that's genuinely outperforming its own expectations.

And this is the piece I think investors sometimes underweight — Mounjaro's global rollout is still in relatively early innings in a lot of these markets. Management basically said future growth outside the U.S. is going to come from market penetration, not just new country launches, since most of the big launch wave already happened last year.

Yeah, he pointed to a few real factors — there were some one-time favorable adjustments to rebate and discount estimates this quarter that won't repeat, last year's back half had a huge bolus of new-market Mounjaro launches that's now lapped, and there's normal seasonality — European summer holidays hit Q3, and diabetes has its own seasonal pattern in Q4. So it's less "conservative sandbagging" and more "the comp gets harder."

The Medicare GLP-1 Bridge Program is a big deal too — it launched July 1st and gives 20 million eligible Americans coverage for obesity GLP-1s at just $50 a month out-of-pocket. That's a 35% expansion in coverage overnight. Early signs are heavily skewed toward injectables — about 80% — but they're seeing real new-patient uptake on both fronts.

On the pipeline side, retatrutide is the one to watch. Three positive Phase III trials — TRIUMPH-1, 2, and 3 — showing weight loss approaching bariatric surgery levels at the top dose. They're targeting a U.S. submission in Q1 2027, and there's an interesting subplot: Lilly's fighting to get it classified as a biologic — a BLA — rather than a small molecule, which has real regulatory and exclusivity implications. That's still being worked out with the FDA.

Management's framing was consistent though — they're chasing big unmet need wherever the science and the price make sense, not chasing a specific therapeutic trend. Jacob Van Naarden, who heads business development, was pretty clear that this isn't a huge strategic pivot, just discipline applied opportunistically.

So stepping back — what does this mean for investors? The core incretin franchise is still compounding at a remarkable rate, both domestically and internationally. Foundayo looks like it's finally turning the corner after a slower-than-hoped start. And the pipeline — retatrutide, oncology readouts, the new vaccine and psychiatry bets — gives Lilly multiple growth vectors beyond the obesity story that's dominated headlines the last couple years.

Before we wrap — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.

We'll be watching the back half of the year closely, especially that Foundayo inflection and the retatrutide filing. Until next time, this has been Beta Finch — thanks for listening, and we'll catch you on the next one.